Ipsen CEO David Loew unpacks six years of radical transformation that enabled a mid-sized, family-controlled biopharma company to take on the biggest competitors in the industry.

Our Guest: David Loew, CEO, Ipsen

David Loew has served as CEO of Ipsen, a publicly listed, family-controlled specialty biopharma group (~6,000 employees, ~€4 billion revenue, operations in 40 countries, products in 100 countries), since July 2020. He joined Ipsen from Sanofi, where he led Sanofi Pasteur, the company's vaccines division, for four years, and previously spent more than 20 years at Roche across various roles and geographies.